

DOCKET NO. PRD2172USPCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Lieven Meerpoel et a.

Serial No. : Not Assigned

Art Unit: Not Assigned

Filed : Herewith

Examiner: Not Assigned

For : N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES  
AS INHIBITORS OF APOLIPOPROTEIN B

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as express mail in an envelope addressed  
to: Mail Stop PCT, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May 24, 2006

(Date of Deposit)

David Knasiak, Reg. No. 45,991

(Name of applicant, assignee, or Registered Representative)

/David Knasiak/

(Signature)

May 24, 2006

(Date of Signature)

Commissioner for Patents  
Alexandria, VA. 22313

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application; or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

DOCKET NO. PRD2172USPCT

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows: See attached Abstracts.

☒ Attached is a copy of a search report(s) from a corresponding patent application(s), which is listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2172USPCT/DK. This form is submitted in triplicate.

Respectfully submitted,

/David Knasiak/  
David Knasiak  
Reg. No. 45,991  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1522  
DATED: May 24, 2006

10/580530

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Not yet Assigned

May 24, 2006

Lieven Meerpoel et al

Not yet Assigned

Not yet Assigned

PRD 2172USPCT

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
		WO	02/081460	A1	Janssen Pharmaceutica N.V..	10-17-2002		
		WO	03/048121	A1	Glaxo Group Ltd.	06-12-2003		
		WO	01/96327	A1	Glaxo Group Ltd.	12-20-2001		

[illegible]

1 Unique citation designation number. 2 See attached

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the

appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of

time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

**IAP9 Rec'd PCT/PTO 24 MAY 2006**

<p>SUBMISSION UNDER MPEP 609 D</p> <p>Page 1 of 1</p>	<i>Application Number</i>	Not yet Assigned
	<i>Filing Date</i>	May 24, 2006
	<i>First Named Inventor</i>	Lieven Meerpoel et al.
	<i>Group Art Unit</i>	Not yet Assigned
	<i>Examiner Name</i>	Not yet Assigned
	<i>Attorney Docket Number</i>	PRD 2172USPCT

[illegible][illegible][illegible]

Examiner Signature	Date Considered
-----------------------	--------------------